Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

Conclusions. Clinical success was similar between patients receiving ceftazidime/avibactam and meropenem/vaborbactam for treatment of CRE infections, despite ceftazidime/avibactam being used more often as combination therapy. Development of resistance was more common with ceftazidime/avibactam monotherapy.
PMID: 32094128 [PubMed - as supplied by publisher]

Source: Antimicrobial Agents and Chemotherapy - February 23, 2020 Category: Microbiology Authors: Ackley R, Roshdy D, Meredith J, Minor S, Anderson WE, Capraro GA, Polk C Tags: Antimicrob Agents Chemother Source Type: research